Third, such treatment will fully rely on heterogeneous opto-TrkA expression and will not depend on low expression of endogenous TrkA receptors in the early stages of Alzheimer's disease. This evidence concerns the gene NTRK1 and early-onset autosomal dominant Alzheimer disease.